Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 3, 2009, Pages 285-290

  Huang, Liusheng ^a   Marzan, Florence ^a   Jayewardene, Anura L ^a   Lizak, Patricia S ^a   Li, Xiaohua ^a   Aweeka, Francesca T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human plasma; Isoniazid; LC MS MS; Method development; Nialamide; Silica column

Indexed keywords

HUMAN PLASMA; ISONIAZID; LC-MS/MS; METHOD DEVELOPMENT; NIALAMIDE; SILICA COLUMN;

CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; HYDRAZINE; HYDROPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDES; PLASMA (HUMAN); PLASMA DIAGNOSTICS; PLASMAS; SILICA;

PLASMA STABILITY;

ABACAVIR; AMPRENAVIR; ATAZANAVIR; EFAVIRENZ; INDINAVIR; ISONIAZID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NIALAMIDE; RITONAVIR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTITUBERCULAR AGENTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; ISONIAZID; LINEAR MODELS; NIALAMIDE; PHYSICOCHEMICAL PHENOMENA; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 58149194518     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.12.024     Document Type: Article

References (12)

1. Weber W.W., and Hein D.W. Clin. Pharmacokinet. 4 (1979) 401
2. Grosset J.H. Rev. Infect. Dis. 11 (Suppl 2) (1989) S347-S352
3. In: Budavari S. (Ed). The Merck Index. 12th ed. (1996) p. 5204
4. Smith P.J., van Dyk J., and Fredericks A. Int. J. Tuberc. Lung Dis. 3 (1999) S325
5. Unsalan S., Sancar M., Bekce B., Clark P.M., Karagoz T., Izzettin F.V., and Rollas S. Chromatographia 61 (2005) 595
6. Olson W.A., Dayton P.G., Israilli Z.H., and Pruitt A.W. Clin. Chem. 23 (1977) 745
7. Delahunty T., Lee B., and Conte J.E. J. Chromatogr. B 705 (1998) 323
8. Ng K.Y., Zhou H.Y., Zhang Y.L., Hybertson B., Randolph T., and Christians U. J. Chromatogr. B 847 (2007) 188
9. Chen X.Y., Song B., Jiang H.J., Yu K., and Zhong D.F. Rapid Commun. Mass Spectrom. 19 (2005) 2591
10. Song S.H., Jun S.H., Park K.U., Yoon Y., Lee J.H., Kim J.Q., and Song J. Rapid Commun. Mass Spectrom. 21 (2007) 1331
11. Li A.C., Junga H., Shou W.Z., Bryant M.S., Jiang X., and Naidong W. Rapid Commun. Mass Spectrom. 18 (2004) 2343
12. ACTG guidelines for method development and validation based on (and including) FDA guidelines dated by 2001, Version 2 (2005).